Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.
Nadal E, Saleh M, Aix SP, Ochoa-de-Olza M, Patel SP, Antonia S, Zhao Y, Gueorguieva I, Man M, Estrem ST, Liu J, Avsar E, Lin WH, Benhadji KA, Gandhi L, Guba SC, Diaz IA. Nadal E, et al. Among authors: ochoa de olza m. BMC Cancer. 2023 Jul 28;23(1):708. doi: 10.1186/s12885-023-11153-1. BMC Cancer. 2023. PMID: 37507657 Free PMC article. Clinical Trial.
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma.
García Del Muro X, Gallardo E, García Carbonero I, Laínez N, José Méndez M, Maroto P, Ochoa de Olza M, Puente J, Reynes G, Rubio J, Santander C, Suárez C, Vázquez Estévez S, Castellano D. García Del Muro X, et al. Among authors: ochoa de olza m. Cancer Chemother Pharmacol. 2014 Jun;73(6):1095-107. doi: 10.1007/s00280-014-2413-0. Epub 2014 Feb 16. Cancer Chemother Pharmacol. 2014. PMID: 24531612 Review.
Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics.
Lozano-Rabella M, Garcia-Garijo A, Palomero J, Yuste-Estevanez A, Erhard F, Farriol-Duran R, Martín-Liberal J, Ochoa-de-Olza M, Matos I, Gartner JJ, Ghosh M, Canals F, Vidal A, Piulats JM, Matías-Guiu X, Brana I, Muñoz-Couselo E, Garralda E, Schlosser A, Gros A. Lozano-Rabella M, et al. Among authors: ochoa de olza m. Clin Cancer Res. 2023 Jun 13;29(12):2250-2265. doi: 10.1158/1078-0432.CCR-22-3298. Clin Cancer Res. 2023. PMID: 36749875 Free PMC article.
Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients.
Jiménez-Valerio G, Martínez-Lozano M, Bassani N, Vidal A, Ochoa-de-Olza M, Suárez C, García-Del-Muro X, Carles J, Viñals F, Graupera M, Indraccolo S, Casanovas O. Jiménez-Valerio G, et al. Among authors: ochoa de olza m. Cell Rep. 2016 May 10;15(6):1134-43. doi: 10.1016/j.celrep.2016.04.015. Epub 2016 Apr 28. Cell Rep. 2016. PMID: 27134180 Free PMC article.
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.
Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, Cervantes A, Ochoa de Olza M, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott D, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey K, Mahrus S, Morley R, Pirzkall A, Davis SL. Jung KH, et al. Among authors: ochoa de olza m. Clin Cancer Res. 2019 Jun 1;25(11):3220-3228. doi: 10.1158/1078-0432.CCR-18-2740. Epub 2019 Feb 15. Clin Cancer Res. 2019. PMID: 30770348 Free PMC article. Clinical Trial.
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.
de Morrée ES, Vogelzang NJ, Petrylak DP, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, Ochoa de Olza M, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, Li JS, de Wit R. de Morrée ES, et al. Among authors: de wit r, ochoa de olza m. JAMA Oncol. 2017 Jan 1;3(1):68-75. doi: 10.1001/jamaoncol.2016.3000. JAMA Oncol. 2017. PMID: 27560549 Clinical Trial.
Immuno-Oncology: The Third Paradigm in Early Drug Development.
Martin-Liberal J, Hierro C, Ochoa de Olza M, Rodon J. Martin-Liberal J, et al. Among authors: ochoa de olza m. Target Oncol. 2017 Apr;12(2):125-138. doi: 10.1007/s11523-016-0471-4. Target Oncol. 2017. PMID: 27995439
36 results